SG11202003273PA - Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same - Google Patents
Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising sameInfo
- Publication number
- SG11202003273PA SG11202003273PA SG11202003273PA SG11202003273PA SG11202003273PA SG 11202003273P A SG11202003273P A SG 11202003273PA SG 11202003273P A SG11202003273P A SG 11202003273PA SG 11202003273P A SG11202003273P A SG 11202003273PA SG 11202003273P A SG11202003273P A SG 11202003273PA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- same
- pharmaceutical composition
- cancer treatment
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170136564A KR101973060B1 (ko) | 2017-10-20 | 2017-10-20 | 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| PCT/KR2018/012492 WO2019078697A2 (fr) | 2017-10-20 | 2018-10-22 | Anticorps anti-cd3 et composition pharmaceutique destinée au traitement du cancer, contenant ledit anticorps |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003273PA true SG11202003273PA (en) | 2020-05-28 |
Family
ID=66173409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003273PA SG11202003273PA (en) | 2017-10-20 | 2018-10-22 | Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11498965B2 (fr) |
| EP (1) | EP3699192A4 (fr) |
| JP (1) | JP7024072B2 (fr) |
| KR (1) | KR101973060B1 (fr) |
| CN (1) | CN111315779B (fr) |
| AU (1) | AU2018353787B2 (fr) |
| BR (1) | BR112020007770A2 (fr) |
| CA (1) | CA3077007C (fr) |
| EA (1) | EA202090944A1 (fr) |
| IL (1) | IL274007A (fr) |
| MX (1) | MX2020003947A (fr) |
| SG (1) | SG11202003273PA (fr) |
| WO (1) | WO2019078697A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020236797A1 (fr) * | 2019-05-21 | 2020-11-26 | Novartis Ag | Domaines de cd58 variants et leurs utilisations |
| CA3196933A1 (fr) * | 2020-09-29 | 2022-04-07 | Innovent Biologics (Suzhou) Co., Ltd. | Anticorps anti-cd3 et ses utilisations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003243138A1 (en) * | 2002-03-26 | 2003-10-13 | Trubion Pharmaceuticals, Inc. | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb |
| AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
| CN103842383B (zh) * | 2011-05-16 | 2017-11-03 | 健能隆医药技术（上海）有限公司 | 多特异性fab融合蛋白及其使用方法 |
| ME03440B (fr) * | 2011-05-21 | 2020-01-20 | Macrogenics Inc | Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| EP3693385A1 (fr) * | 2013-07-05 | 2020-08-12 | Genmab A/S | Anticorps anti-cd3 humanisés ou chimères |
| EP2839842A1 (fr) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations |
| ES2811923T3 (es) * | 2013-12-17 | 2021-03-15 | Genentech Inc | Anticuerpos anti-CD3 y métodos de uso |
| JP2017520575A (ja) * | 2014-07-01 | 2017-07-27 | ファイザー・インク | 二重特異的ヘテロ二量体ダイアボディおよびその使用 |
| EP2982693A1 (fr) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | Domaine de liaison CD3 |
| CN109069635B (zh) | 2016-02-04 | 2023-09-26 | 斯克利普斯研究所 | 人源化抗cd3抗体、偶联物及其用途 |
| KR102329635B1 (ko) * | 2017-04-24 | 2021-11-22 | 재단법인 목암생명과학연구소 | Her3 및 cd3에 결합하는 이중특이적 항체 |
-
2017
- 2017-10-20 KR KR1020170136564A patent/KR101973060B1/ko active IP Right Grant
-
2018
- 2018-10-22 JP JP2020521940A patent/JP7024072B2/ja active Active
- 2018-10-22 AU AU2018353787A patent/AU2018353787B2/en active Active
- 2018-10-22 US US16/754,431 patent/US11498965B2/en active Active
- 2018-10-22 MX MX2020003947A patent/MX2020003947A/es unknown
- 2018-10-22 EP EP18867685.2A patent/EP3699192A4/fr active Pending
- 2018-10-22 EA EA202090944A patent/EA202090944A1/ru unknown
- 2018-10-22 BR BR112020007770-4A patent/BR112020007770A2/pt unknown
- 2018-10-22 CA CA3077007A patent/CA3077007C/fr active Active
- 2018-10-22 WO PCT/KR2018/012492 patent/WO2019078697A2/fr unknown
- 2018-10-22 CN CN201880068391.7A patent/CN111315779B/zh active Active
- 2018-10-22 SG SG11202003273PA patent/SG11202003273PA/en unknown
-
2020
- 2020-04-16 IL IL274007A patent/IL274007A/en unknown
-
2022
- 2022-10-03 US US17/958,995 patent/US20230192851A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018353787B2 (en) | 2022-02-24 |
| KR101973060B1 (ko) | 2019-04-26 |
| EP3699192A4 (fr) | 2021-10-20 |
| US20200317779A1 (en) | 2020-10-08 |
| WO2019078697A2 (fr) | 2019-04-25 |
| JP7024072B2 (ja) | 2022-02-22 |
| WO2019078697A8 (fr) | 2020-04-09 |
| EA202090944A1 (ru) | 2020-07-16 |
| US11498965B2 (en) | 2022-11-15 |
| CA3077007A1 (fr) | 2019-04-25 |
| MX2020003947A (es) | 2020-08-03 |
| CN111315779A (zh) | 2020-06-19 |
| WO2019078697A3 (fr) | 2019-07-04 |
| BR112020007770A2 (pt) | 2020-10-20 |
| JP2021501571A (ja) | 2021-01-21 |
| CA3077007C (fr) | 2023-04-18 |
| US20230192851A1 (en) | 2023-06-22 |
| AU2018353787A1 (en) | 2020-05-21 |
| CN111315779B (zh) | 2024-06-21 |
| IL274007A (en) | 2020-05-31 |
| EP3699192A2 (fr) | 2020-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE054316T2 (hu) | Gyógyászati készítmény rák kezelésére | |
| HK1257056A1 (zh) | 抗dll3抗體藥物綴合物以及使用方法 | |
| EP3524268A4 (fr) | Utilisation d'une combinaison d'un anticorps anti-pd-1 et d'un inhibiteur de vegfr dans la préparation d'un médicament pour le traitement de cancers | |
| HK1247848A1 (zh) | 抗pd-1和抗m-csf抗體在治療癌症中的聯合應用 | |
| IL311136A (en) | Anti-CD3 antibody for use in the treatment or prevention of cancer and molecules containing the antibody | |
| IL260474B (en) | Antibodies specific to cadherin-17 and cytotoxic cells for cancer treatment | |
| IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
| EP3502142A4 (fr) | Anticorps bispécifique et conjugué d'anticorps pour thérapie tumorale et leurs utilisations | |
| IL274008A (en) | Anti-MSLN antibody and a pharmaceutical preparation containing it for the treatment of cancer | |
| IL272669A (en) | Combination therapy with a combination of anti-CSF1R and anti-PD-1 antibodies for pancreatic cancer | |
| EP3708173C0 (fr) | Composition pharmaceutique comprenant du mirna-3140 pour le traitement du cancer | |
| IL275525A (en) | A pharmaceutical preparation for the treatment of cancer | |
| ZA201802618B (en) | Anti-cd43 antibody and use thereof for cancer treatment | |
| IL274007A (en) | Anti-CD3 antibody and a pharmaceutical preparation containing it for the treatment of cancer | |
| PT3290051T (pt) | Composição farmacêutica para o tratamento e/ou prevenção de cancro | |
| EP3563856A4 (fr) | Composition pharmaceutique destinée au traitement du cancer, et utilisation correspondante | |
| EP3647325A4 (fr) | Composition pharmaceutique comprenant un anticorps pcsk-9 et son utilisation | |
| EP3406626A4 (fr) | Peptide pour traitement du cancer, et composition pharmaceutique contenant celui-ci | |
| IL249860A0 (en) | Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer | |
| EP3372233A4 (fr) | Composition pharmaceutique pour le traitement et/ou la prévention du cancer | |
| EP3441465A4 (fr) | Composition médicamenteuse pour traitement du cancer mettant en oeuvre un anticorps anti-mct5 | |
| HK1254918A1 (zh) | Etar抗體，其藥物組合物及其應用 | |
| GB201718925D0 (en) | Pharmaceutical composition suitable for gastric cancer treatment and/or prevention | |
| EP3498284A4 (fr) | Composition pharmaceutique pour le traitement et/ou la prévention du cancer | |
| GB201713936D0 (en) | Pharmaceutical combinations for the treatment of cancer |